{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:38:12Z","timestamp":1792636692021,"version":"4.5.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"17","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T00:00:00Z","timestamp":1724630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.heliyon.2024.e36955","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T05:12:14Z","timestamp":1724735534000},"page":"e36955","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["The first case of multiple myeloma treated with ASCT followed by Anti-BCMA CAR-T cells using retrovirus vector: A case report"],"prefix":"10.1016","volume":"10","author":[{"given":"Liqiong","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxiang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiting","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanhuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2997-4573","authenticated-orcid":false,"given":"Yuanyuan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8029-2457","authenticated-orcid":false,"given":"Zhi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e36955_bib1","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/CM9.0000000000001474","article-title":"Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020","volume":"134","author":"Cao","year":"2021","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.heliyon.2024.e36955_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41408-023-00785-y","article-title":"Defining drug\/drug class refractoriness vs lines of therapy in relapsed\/refractory multiple myeloma","volume":"13","author":"Goel","year":"2023","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.heliyon.2024.e36955_bib3","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/bjh.18185","article-title":"How I treat triple-class refractory multiple myeloma","volume":"198","author":"Costa","year":"2022","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.heliyon.2024.e36955_bib4","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41392-019-0070-9","article-title":"Genetically engineered T cells for cancer immunotherapy","volume":"4","author":"Li","year":"2019","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.heliyon.2024.e36955_bib5","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.7150\/ijms.46811","article-title":"Efficacy and safety of CAR-T therapy for relapse or refractory multiple myeloma: a systematic review and meta-analysis","volume":"18","author":"Yang","year":"2021","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.heliyon.2024.e36955_bib6","article-title":"Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: a systematic review and meta-analysis","author":"Akhtar","year":"2023","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.heliyon.2024.e36955_bib7","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1600-065X.2011.01067.x","article-title":"Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease","volume":"244","author":"Rickert","year":"2011","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.heliyon.2024.e36955_bib8","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1959102","article-title":"Novel BCMA-OR-CD38 tandem-dual chimeric antigen receptor T cells robustly control multiple myeloma","volume":"10","author":"Feng","year":"2021","journal-title":"OncoImmunology"},{"key":"10.1016\/j.heliyon.2024.e36955_bib9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e36955_bib10","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13045-019-0823-5","article-title":"Chimeric antigen receptor T cell therapies for multiple myeloma","volume":"12","author":"Wu","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.heliyon.2024.e36955_bib11","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2024.e36955_bib12","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e36955_bib13","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e36955_bib14","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jtct.2022.07.015","article-title":"Chimeric antigen receptor T cell therapy versus hematopoietic stem cell transplantation: an evolving perspective","volume":"28","author":"Goldsmith","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.heliyon.2024.e36955_bib15","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1182\/blood.2023020571","article-title":"Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells","volume":"142","author":"Karschnia","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e36955_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2020.101430","article-title":"New viral vectors for infectious diseases and cancer","volume":"50","author":"Sasso","year":"2020","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.heliyon.2024.e36955_bib17","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1186\/s12967-022-03729-5","article-title":"Genome-wide profiling of retroviral DNA integration and its effect on clinical pre-infusion CAR T-cell products","volume":"20","author":"Shao","year":"2022","journal-title":"J. Transl. Med."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024129866?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024129866?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T21:35:46Z","timestamp":1790544946000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024129866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":17,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2405844024129866"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e36955","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The first case of multiple myeloma treated with ASCT followed by Anti-BCMA CAR-T cells using retrovirus vector: A case report","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e36955","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e36955"}}